Aetna to waive copays for opioid overdose antidote

Starting January 1, Aetna will waive copays for naloxone (Narcan—Adapt Pharma) for its fully insured commercial members. Data show that just over a third of Aetna members who were prescribed Narcan in the first 6 months of the year did not pick up their prescription, and cost was one reason.

Starting January 1, Aetna will waive copays for naloxone (Narcan—Adapt Pharma) for its fully insured commercial members. Data show that just over a third of Aetna members who were prescribed Narcan in the first 6 months of the year did not pick up their prescription, and cost was one reason. Members had a 77% abandonment rate if the copay for the opioid overdose reversal drug was between $100 and $150, while the abandonment rate dropped to 46% when the copay was between $40 and $50. Also starting January 1, Aetna said it will limit the number of opioids prescribed for acute pain and post-surgery patients to a 7-day supply.